The main goal of this study was to assess the reduction of complications and costs with continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in uncontrolled type 2 diabetic patients (T2D) in the UK.
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RESULTS
CSII usage allows a reduction of diabetes-related complications. At 5 years, incidence reductions in complications associated with eye diseases, renal diseases, ulcer/amputation and cardiovascular diseases (CVD) were 24%, 26%, 19% and 10% (Figures 1 and 2 ). These reductions in complications translate to a 12% decrease in healthcare costs per patient over 5 years. Over a lifetime horizon, the cumulative incidence of CVD for CSII is higher than the one for 
